Regeneron Pharmaceuticals Inc. (REGN) (REGN)
Sanofi (SAN) and won U.S. clearance for Zaltrap as a treatment for patients with advanced colorectal cancer who haven’t been helped by previous therapy.
The Food and Drug Administration approved the drug for use in combination with chemotherapy as a so-called second-line treatment for patients whose colorectal cancer has spread to other parts of the body, the agency said today in a statement. Regeneron also sells the medicine, known by the scientific name aflibercept, under the name Eylea to treat wet age-related macular degeneration, a condition that causes vision loss.
Read the full story: http://tinyurl.com/cu3d22j
Source: Bloomberg Businessweek